Develops genetic medicines for people with rare neurological diseases, including gene therapy for Rett syndrome.
10-K for FY2025, filed Mar 24, 2026Despite recent scientific advances in genetics, most neurological diseases, particularly those with devastating consequences to patients…View ↗
Our first clinical-stage program, NGN-401 in development for the treatment of Rett syndrome, utilizes the EXACT technology and…View ↗
Our pipeline is focused on the development of genetic medicines for severe neurological diseases. Our most advanced program, NGN‑401, is in…View ↗
10-Q for Q3 FY2026, filed Nov 9, 2026
−$29MView ↗
From cancer immunotherapies to neurological gene therapies
The older report described a focus on computationally designed cytokine mimetics for cancer and inflammatory conditions, with research suspended while strategic alternatives were considered. The latest report describes genetic medicines for rare neurological diseases, led by a Rett syndrome gene therapy program.
10-K for FY2022, filed Mar 20, 2023 10-K for FY2025, filed Mar 24, 2026We are a biopharmaceutical company that has focused on creating next generation immunotherapies for cancer, inflammation, and autoimmunity…View ↗
Our work has been primarily focused on key cytokine mimetics, which we refer to as Neoleukin de novo cytokine mimetics, that can be…View ↗
Following the decision by our Board of Directors in March 2023 to further restructure the Company to conserve capital and focus on…View ↗
Competes with Taysha Gene Therapies
10-K for FY2025, filed Mar 24, 2026While no disease-modifying therapies are currently available on the market for the treatment of Rett syndrome, we are aware of several…View ↗
Loading...